|  | 
| MechanismHMG-CoA reductase inhibitors [+2]  | 
|  | 
|  | 
|  | 
|  | 
| Drug Highest PhaseApproved | 
| First Approval Ctry. / Loc.Switzerland | 
| First Approval Date25 Jun 1990 | 
100 Clinical Results associated with Sigillata Ltd.
0  Patents (Medical) associated with Sigillata Ltd.
100 Deals associated with Sigillata Ltd.
100 Translational Medicine associated with Sigillata Ltd.